Literature DB >> 25754230

A histological and functional description of the tissue causing chronic postthrombotic venous obstruction.

Anthony J Comerota1, Carson Oostra2, Ziad Fayad2, William Gunning3, Peter Henke4, Catherine Luke4, Amy Lynn5, Fedor Lurie2.   

Abstract

BACKGROUND: Postthrombotic intraluminal tissue causing postthrombotic syndrome (PTS) has not been well described. This study defines its histological characteristics and assess whether tissue function evolves over time.
METHODS: Specimens from 18 common femoral veins (CFV) from 16 patients obtained during CFV endovenectomy and iliocaval recanalization were examined. Phase 1 used hematoxylin and eosin and Masson's trichrome stains for collagen, immunohistochemical, and Von Kossa stains. Phase 2 examined young (≤ one year) and mature (≥10years from acute DVT) specimens to evaluate evolution of endothelial function. Antibodies to four biomarkers were used to examine specific functions of endothelial cells lining neovessels and recanalization channels (RC).
RESULTS: Phase 1: Specimens demonstrated 80-90% of collagen type I, 10-20% of collagen type III, and dystrophic calcification. Neovessels and RC were in close proximity to each other. Thrombus and smooth muscle cells were absent, but white blood cells were present. Phase 2: VEGFR2 receptor uptake was more abundant in neovessels than RC and more prominent in younger specimens. Neovascular, nonchannel cells were observed more frequently in young specimens. CD-31 was similar in young and mature specimens. TIE-2 and von Willebrand factor antibodies had greater uptake in mature specimens.
CONCLUSION: Tissue causing chronic postthrombotic venous obstruction is predominantly type I collagen. Neovascularization and recanalization occur in close proximity. The biomarker for neovascularization and angiogenesis (VEGFR2) was more prominent in young specimens whereas TIE-2, a stabilizing biomarker and vWF were more frequently observed in mature specimens.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Collagen; Iliofemoral DVT; Postthrombotic syndrome; Thrombosis; Venous hypertension; Venous obstruction

Mesh:

Substances:

Year:  2015        PMID: 25754230     DOI: 10.1016/j.thromres.2015.02.026

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Modulation of interleukin-6 and its effect on late vein wall injury in a stasis mouse model of deep vein thrombosis.

Authors:  Abigail R Dowling; Catherine E Luke; Qing Cai; Antonio M Pellerito; Andrea T Obi; Peter K Henke
Journal:  JVS Vasc Sci       Date:  2022-04-22

Review 2.  The Dural AV-Fistula (DAVF), the Most Frequent Acquired Vascular Malformation of the Central Nervous System (CNS).

Authors:  I Wanke; D A Rüfenacht
Journal:  Clin Neuroradiol       Date:  2015-08-26       Impact factor: 3.649

3.  Time-Restricted Salutary Effects of Blood Flow Restoration on Venous Thrombosis and Vein Wall Injury in Mouse and Human Subjects.

Authors:  Wenzhu Li; Chase W Kessinger; Makoto Orii; Hang Lee; Lang Wang; Ido Weinberg; Michael R Jaff; Guy L Reed; Peter Libby; Ahmed Tawakol; Peter K Henke; Farouc A Jaffer
Journal:  Circulation       Date:  2021-01-15       Impact factor: 29.690

4.  Venous stent patency may be affected by collateral vein lumen size.

Authors:  Timme Maj van Vuuren; Suat Doganci; Irwin M Toonder; Rick De Graaf; Cees Ha Wittens
Journal:  Phlebology       Date:  2018-03-07       Impact factor: 1.740

5.  Ultrasound-Accelerated Thrombolysis and Venoplasty for the Treatment of the Postthrombotic Syndrome: Results of the ACCESS PTS Study.

Authors:  Mark J Garcia; Keith M Sterling; Susan R Kahn; Anthony J Comerota; Michael R Jaff; Kenneth Ouriel; Ido Weinberg
Journal:  J Am Heart Assoc       Date:  2020-01-25       Impact factor: 5.501

Review 6.  Resolution of Deep Venous Thrombosis: Proposed Immune Paradigms.

Authors:  J Matthew Nicklas; Aviva E Gordon; Peter K Henke
Journal:  Int J Mol Sci       Date:  2020-03-18       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.